Summit Therapeutics Inc.
SMMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.01 | -21.34 | -14.34 |
| FCF Yield | -0.62% | -0.42% | -0.43% | -0.37% |
| EV / EBITDA | -65.27 | -27.42 | -223.13 | -213.70 |
| Quality | ||||
| ROIC | -117.39% | -213.03% | -18.97% | -16.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.12 | 0.97 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -42.47% | -8.37% | -26.50% | -60.39% |
| Safety | ||||
| Net Debt / EBITDA | 1.01 | 0.52 | 3.26 | 1.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -7,290.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -47,667.86 | -55,902.16 | -17,978.40 | -27.93 |